Covered recipient · General Payments record
DAVID M WATERHOUSE
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$153,208.15
102 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $85,643.00 | 40 |
| Consulting Fee | $65,126.00 | 38 |
| Travel and Lodging | $1,614.61 | 5 |
| Food and Beverage | $790.25 | 16 |
| Education | $34.29 | 3 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $49,993.00 | 21 |
| E.R. Squibb & Sons, L.L.C. | $28,610.43 | 25 |
| Janssen Biotech, Inc. | $26,573.73 | 24 |
| JAZZ PHARMACEUTICALS INC. | $11,065.00 | 2 |
| Merck Sharp & Dohme Corporation | $8,845.87 | 4 |
| Lilly USA, LLC | $5,950.00 | 4 |
| EMD Serono, Inc. | $5,520.00 | 5 |
| Novartis Pharmaceuticals Corporation | $3,946.59 | 3 |
| AstraZeneca Pharmaceuticals LP | $3,859.02 | 4 |
| Eisai Inc. | $2,970.00 | 2 |
| Regeneron Healthcare Solutions, Inc. | $2,292.50 | 1 |
| GENZYME CORPORATION | $2,108.00 | 1 |
| Gilead Sciences, Inc. | $1,331.92 | 2 |
| Myovant Sciences Inc. | $94.57 | 1 |
| Genentech USA, Inc. | $18.08 | 1 |
| Astellas Pharma US Inc | $17.94 | 1 |
| Epizyme, Inc., | $11.50 | 1 |
Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID M WATERHOUSE
NPI 1578557864 · CMS profile ID 252415
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
CINCINNATI, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1578557864?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID M WATERHOUSE, NPI 1578557864, CMS profile ID 252415. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578557864?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). DAVID M WATERHOUSE, NPI 1578557864, CMS profile ID 252415. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578557864?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- DAVID M WATERHOUSE, NPI 1578557864, CMS profile ID 252415, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1578557864?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
102 matching records · $153,208.15 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 102.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $13.50 | 08/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788403389 | CMS |
| E.R. Squibb & Sons, L.L.C. | $8.00 | 07/30/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783567333 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.44 | 07/30/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783567339 | CMS |
| EMD Serono, Inc. | $1,380.00 | 07/30/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849178345 | CMS |
| E.R. Squibb & Sons, L.L.C. | $400.00 | 07/29/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783567327 | CMS |
| E.R. Squibb & Sons, L.L.C. | $5,300.00 | 07/27/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783567337 | CMS |
| EMD Serono, Inc. | $690.00 | 07/23/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849149359 | CMS |
| GENZYME CORPORATION | $2,108.00 | 07/21/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843762031 | CMS |
| Novartis Pharmaceuticals Corporation | $1,965.00 | 07/21/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813352585 | CMS |
| E.R. Squibb & Sons, L.L.C. | $400.00 | 07/16/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783567319 | CMS |
| Janssen Biotech, Inc. | $1,200.00 | 07/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788403363 | CMS |
| Janssen Biotech, Inc. | $5,000.00 | 07/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788403371 | CMS |
| Novartis Pharmaceuticals Corporation | $16.59 | 07/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813352589 | CMS |
| E.R. Squibb & Sons, L.L.C. | $121.07 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783567335 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2,292.50 | 07/09/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809634765 | CMS |
| E.R. Squibb & Sons, L.L.C. | $600.00 | 07/08/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783567379 | CMS |
| Janssen Biotech, Inc. | $110.81 | 07/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788403367 | CMS |
| Janssen Biotech, Inc. | $1,004.85 | 07/07/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788403369 | CMS |
| Merck Sharp & Dohme Corporation | $3,355.00 | 07/07/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848439321 | CMS |
| Janssen Biotech, Inc. | $600.00 | 06/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788403361 | CMS |
| Janssen Biotech, Inc. | $42.80 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788403395 | CMS |
| Amgen Inc. | $974.25 | 06/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826323179 | CMS |
| Merck Sharp & Dohme Corporation | $3,355.00 | 06/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848592201 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,650.00 | 06/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783567321 | CMS |
| Gilead Sciences, Inc. | $11.92 | 06/01/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845880757 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,500.00 | 05/19/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783567291 | CMS |
| EMD Serono, Inc. | $690.00 | 05/11/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849180707 | CMS |
| JAZZ PHARMACEUTICALS INC. | $5,500.00 | 05/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845602717 | CMS |
| Janssen Biotech, Inc. | $14.64 | 05/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788403393 | CMS |
| Janssen Biotech, Inc. | $1,200.00 | 05/03/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788403365 | CMS |
| E.R. Squibb & Sons, L.L.C. | $800.00 | 04/29/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783567279 | CMS |
| Myovant Sciences Inc. | $94.57 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834995719 | CMS |
| AstraZeneca Pharmaceuticals LP | $92.48 | 04/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829520863 | CMS |
| Janssen Biotech, Inc. | $1,200.00 | 04/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788403359 | CMS |
| Astellas Pharma US Inc | $17.94 | 04/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821593981 | CMS |
| Merck Sharp & Dohme Corporation | $2,125.00 | 04/01/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848426261 | CMS |
| Eisai Inc. | $1,350.00 | 03/23/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833766427 | CMS |
| Amgen Inc. | $1,947.00 | 03/08/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826530057 | CMS |
| Janssen Biotech, Inc. | $1,200.00 | 03/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788403353 | CMS |
| Janssen Biotech, Inc. | $1,200.00 | 03/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788403355 | CMS |
| Janssen Biotech, Inc. | $1,200.00 | 03/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788403357 | CMS |
| Janssen Biotech, Inc. | $1,860.00 | 03/05/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788403351 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.04 | 02/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830017211 | CMS |
| E.R. Squibb & Sons, L.L.C. | $300.00 | 02/22/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783567391 | CMS |
| Epizyme, Inc., | $11.50 | 02/18/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832343427 | CMS |
| Amgen Inc. | $1,947.00 | 02/10/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826530053 | CMS |
| Amgen Inc. | $1,947.00 | 02/10/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826530055 | CMS |
| E.R. Squibb & Sons, L.L.C. | $200.00 | 02/09/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783567125 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,635.00 | 02/04/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783567259 | CMS |
| Eisai Inc. | $1,620.00 | 02/02/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833762743 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $750.45 | 2 |
| PY2025 | Principal investigator | $427,190.23 | 217 |
| PY2024 | Recipient | $5,775.77 | 2 |
| PY2024 | Principal investigator | $163,925.81 | 53 |
| PY2023 | Principal investigator | $333,707.07 | 39 |
| PY2022 | Principal investigator | $393,722.48 | 177 |
| PY2021 | Principal investigator | $1,407,800.94 | 307 |
| PY2020 | Recipient | $72.50 | 1 |
| PY2020 | Principal investigator | $668,163.27 | 598 |
| PY2019 | Recipient | $162,224.72 | 20 |
| PY2019 | Principal investigator | $1,074,939.27 | 744 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
219 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $425.00 | 12/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754166 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 12/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754168 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184279392 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 12/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228726584 |
| Principal investigator 1 | PFIZER INC. | $50.00 | 12/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228726900 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 12/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228727109 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753462 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 11/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228726656 |
| Principal investigator 1 | PFIZER INC. | $281.00 | 11/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228727413 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 11/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228727843 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $425.00 | 11/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753238 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 11/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753240 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 11/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184257971 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 10/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184253827 |
| Principal investigator 1 | Amgen Inc. | $27,670.00 | 10/24/2025 | Non-covered Recipient Entity US ONC RESEARCH LLC | A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C | No dispute reported | 06/30/2026 | 1246651011 |
| Principal investigator 1 | PFIZER INC. | $125.00 | 10/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228716371 |
| Principal investigator 1 | PFIZER INC. | $200.00 | 10/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228716551 |
| Principal investigator 1 | PFIZER INC. | $1,259.00 | 10/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228716553 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 10/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228723390 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 10/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228724518 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 10/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228726941 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 10/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228726943 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 10/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228727271 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 10/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753950 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 09/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753938 |
| Principal investigator 1 | PFIZER INC. | $125.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228723058 |
| Principal investigator 1 | PFIZER INC. | $518.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228724592 |
| Principal investigator 1 | PFIZER INC. | $2,200.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745351 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745445 |
| Principal investigator 1 | PFIZER INC. | $3,053.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745918 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745942 |
| Principal investigator 1 | PFIZER INC. | $896.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746075 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746138 |
| Principal investigator 1 | PFIZER INC. | $2,042.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746574 |
| Principal investigator 1 | PFIZER INC. | $150.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228747248 |
| Principal investigator 1 | PFIZER INC. | $50.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747587 |
| Principal investigator 1 | PFIZER INC. | $281.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228748077 |
| Principal investigator 1 | PFIZER INC. | $150.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228748206 |
| Principal investigator 1 | PFIZER INC. | $1,760.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228749628 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228749775 |
| Principal investigator 1 | PFIZER INC. | $2,147.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228750422 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228750692 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 09/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228751007 |
| Principal investigator 1 | PFIZER INC. | $1,125.00 | 09/15/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228757385 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 09/15/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228758878 |
| Principal investigator 1 | PFIZER INC. | $235.20 | 09/02/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228749237 |
| Principal investigator 1 | PFIZER INC. | $388.00 | 08/25/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228765799 |
| Principal investigator 1 | PFIZER INC. | $609.00 | 08/25/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228784850 |
| Principal investigator 1 | PFIZER INC. | $3,956.06 | 08/18/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228766101 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 08/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228720261 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 08/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745017 |
| Principal investigator 1 | PFIZER INC. | $1,760.00 | 08/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228745215 |
| Principal investigator 1 | PFIZER INC. | $125.00 | 08/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228745824 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 08/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228749950 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 08/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228750080 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 08/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754160 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 08/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184228487 |
| Principal investigator 1 | PFIZER INC. | $388.00 | 07/21/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228771563 |
| Principal investigator 1 | PFIZER INC. | $388.00 | 07/21/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228772846 |
| Principal investigator 1 | PFIZER INC. | $2,555.00 | 07/21/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228786183 |
| Principal investigator 1 | PFIZER INC. | $3,590.00 | 07/21/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228787115 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 07/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753452 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 07/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228722506 |
| Principal investigator 1 | PFIZER INC. | $1,760.00 | 07/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228745719 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 07/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745786 |
| Principal investigator 1 | PFIZER INC. | $281.00 | 07/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747583 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 07/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228750558 |
| Principal investigator 1 | PFIZER INC. | $125.00 | 07/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228750736 |
| Principal investigator 1 | PFIZER INC. | $200.00 | 07/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228751013 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 07/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184213083 |
| Principal investigator 1 | PFIZER INC. | $5,934.09 | 06/16/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228776871 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 06/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753234 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 06/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745302 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 06/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745623 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 06/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745914 |
| Principal investigator 1 | PFIZER INC. | $2,200.00 | 06/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745946 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 06/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745997 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 06/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746067 |
| Principal investigator 1 | PFIZER INC. | $2,147.00 | 06/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746178 |
| Principal investigator 1 | PFIZER INC. | $3,053.00 | 06/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746350 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 06/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746857 |
| Principal investigator 1 | PFIZER INC. | $2,042.00 | 06/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747707 |
| Principal investigator 1 | PFIZER INC. | $1,760.00 | 06/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228750115 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 06/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228750120 |
| Principal investigator 1 | PFIZER INC. | $125.00 | 06/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228750695 |
| Principal investigator 1 | PFIZER INC. | $518.00 | 06/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228750728 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 06/12/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184206597 |
| Principal investigator 1 | PFIZER INC. | $388.00 | 05/28/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228764179 |
| Principal investigator 1 | PFIZER INC. | $609.00 | 05/28/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228764685 |
| Principal investigator 1 | PFIZER INC. | $2,525.00 | 05/28/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228766045 |
| Principal investigator 1 | PFIZER INC. | $388.00 | 05/28/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228771663 |
| Principal investigator 1 | PFIZER INC. | $3,590.00 | 05/28/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228772288 |
| Principal investigator 1 | PFIZER INC. | $1,125.00 | 05/28/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228777528 |
| Principal investigator 1 | PFIZER INC. | $388.00 | 05/28/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228782671 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,500.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184199049 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,000.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184199051 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,000.00 | 05/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184199053 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 05/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184197769 |
| Principal investigator 1 | PFIZER INC. | $5,869.80 | 05/19/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | MULTIPLE PART CLINICAL TRIAL OF BRENTUXIMAB VEDOTIN IN CLASSICAL HODGKIN LYMPHOMA SUBJECTS | No dispute reported | 06/30/2026 | 1228773052 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $1,890.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753094 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753096 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $425.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754058 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $81.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754060 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $675.00 | 05/16/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754062 |
| Recipient | Amgen Inc. | $43.33 | 05/15/2025 | Covered Recipient Physician | Real world US NSCLC standard of care | No dispute reported | 06/30/2026 | 1246637050 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 05/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745024 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 05/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745218 |
| Principal investigator 1 | PFIZER INC. | $1,760.00 | 05/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228745270 |
| Principal investigator 1 | PFIZER INC. | $125.00 | 05/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228745621 |
| Principal investigator 1 | PFIZER INC. | $200.00 | 05/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228745766 |
| Principal investigator 1 | PFIZER INC. | $1,760.00 | 05/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228745990 |
| Principal investigator 1 | PFIZER INC. | $1,600.00 | 05/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228746182 |
| Principal investigator 1 | PFIZER INC. | $125.00 | 05/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228746693 |
| Principal investigator 1 | PFIZER INC. | $281.00 | 05/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747241 |
| Principal investigator 1 | PFIZER INC. | $1,600.00 | 05/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228747863 |
| Principal investigator 1 | PFIZER INC. | $62.00 | 05/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228748470 |
| Principal investigator 1 | PFIZER INC. | $57.00 | 05/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228749813 |
| Principal investigator 1 | PFIZER INC. | $1,600.00 | 05/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228749817 |
| Principal investigator 1 | PFIZER INC. | $1,600.00 | 05/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228751159 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,200.00 | 05/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184193853 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 05/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184193855 |
| Principal investigator 1 | Amgen Inc. | $44,143.00 | 04/24/2025 | Non-covered Recipient Entity US ONC RESEARCH LLC | A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) | No dispute reported | 06/30/2026 | 1246651024 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 04/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754064 |
| Principal investigator 1 | PFIZER INC. | $2,147.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745020 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745348 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745354 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745911 |
| Principal investigator 1 | PFIZER INC. | $3,053.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746637 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746852 |
| Principal investigator 1 | PFIZER INC. | $400.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228746969 |
| Principal investigator 1 | PFIZER INC. | $1,760.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228747073 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747245 |
| Principal investigator 1 | PFIZER INC. | $2,200.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747457 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747461 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228748081 |
| Principal investigator 1 | PFIZER INC. | $518.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228750733 |
| Principal investigator 1 | PFIZER INC. | $125.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228750841 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228750843 |
| Principal investigator 1 | PFIZER INC. | $2,042.00 | 04/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228750890 |
| Principal investigator 1 | PFIZER INC. | $588.00 | 04/07/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228779311 |
| Principal investigator 1 | PFIZER INC. | $388.00 | 04/07/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228779681 |
| Principal investigator 1 | PFIZER INC. | $388.00 | 04/07/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228781274 |
| Principal investigator 1 | PFIZER INC. | $388.00 | 04/07/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228795845 |
| Principal investigator 1 | PFIZER INC. | $2,555.00 | 04/07/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228800513 |
| Recipient | Amgen Inc. | $707.12 | 03/27/2025 | Covered Recipient Physician | MAIC sotorasib vs adagrasib 2L+ NSCLC | No dispute reported | 06/30/2026 | 1246637048 |
| Principal investigator 1 | PFIZER INC. | $5,934.09 | 03/24/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228795915 |
| Principal investigator 1 | PFIZER INC. | $1,881.60 | 03/17/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228724642 |
| Principal investigator 1 | PFIZER INC. | $2,200.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228720413 |
| Principal investigator 1 | PFIZER INC. | $140.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228720645 |
| Principal investigator 1 | PFIZER INC. | $1,760.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228744559 |
| Principal investigator 1 | PFIZER INC. | $1,497.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228744563 |
| Principal investigator 1 | PFIZER INC. | $2,147.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745583 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745585 |
| Principal investigator 1 | PFIZER INC. | $140.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745590 |
| Principal investigator 1 | PFIZER INC. | $2,042.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745680 |
| Principal investigator 1 | PFIZER INC. | $281.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746079 |
| Principal investigator 1 | PFIZER INC. | $150.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746084 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746088 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746300 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746305 |
| Principal investigator 1 | PFIZER INC. | $40.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746309 |
| Principal investigator 1 | PFIZER INC. | $40.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746860 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746974 |
| Principal investigator 1 | PFIZER INC. | $50.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747028 |
| Principal investigator 1 | PFIZER INC. | $896.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747138 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747146 |
| Principal investigator 1 | PFIZER INC. | $40.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747704 |
| Principal investigator 1 | PFIZER INC. | $125.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228748212 |
| Principal investigator 1 | PFIZER INC. | $40.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228749624 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228750837 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228751166 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 03/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251754204 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,100.00 | 03/03/2025 | Non-covered Recipient Entity Us Oncology Res Llc | A Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) | No dispute reported | 06/30/2026 | 1235992155 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228719373 |
| Principal investigator 1 | PFIZER INC. | $200.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228724234 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745298 |
| Principal investigator 1 | PFIZER INC. | $1,760.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228745442 |
| Principal investigator 1 | PFIZER INC. | $2,147.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745548 |
| Principal investigator 1 | PFIZER INC. | $125.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228745684 |
| Principal investigator 1 | PFIZER INC. | $125.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228745738 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745770 |
| Principal investigator 1 | PFIZER INC. | $1,600.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228745820 |
| Principal investigator 1 | PFIZER INC. | $3,053.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745950 |
| Principal investigator 1 | PFIZER INC. | $1,760.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228746071 |
| Principal investigator 1 | PFIZER INC. | $1,600.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228746569 |
| Principal investigator 1 | PFIZER INC. | $2,042.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746633 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747033 |
| Principal investigator 1 | PFIZER INC. | $518.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747700 |
| Principal investigator 1 | PFIZER INC. | $330.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228749953 |
| Principal investigator 1 | PFIZER INC. | $2,200.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228750124 |
| Principal investigator 1 | PFIZER INC. | $20.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228750383 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228750389 |
| Principal investigator 1 | PFIZER INC. | $1,600.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228751017 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228751480 |
| Principal investigator 1 | PFIZER INC. | $1,600.00 | 02/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228751484 |
| Principal investigator 1 | PFIZER INC. | $10,446.45 | 02/03/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228800046 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 01/31/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753534 |
| Principal investigator 1 | Amgen Inc. | $19,132.90 | 01/27/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INCORPORATED | A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) | No dispute reported | 06/30/2026 | 1246645954 |
| Principal investigator 1 | Amgen Inc. | $28,147.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1246645968 |
| Principal investigator 1 | Amgen Inc. | $30,742.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) | No dispute reported | 06/30/2026 | 1246645979 |
| Principal investigator 1 | Amgen Inc. | $116.69 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | MyLung Consortium Study (USOR) | No dispute reported | 06/30/2026 | 1246645999 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $160.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY ASSOC | A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community | No dispute reported | 06/30/2026 | 1185552495 |
| Principal investigator 1 | Eli Lilly and Company | $133.35 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE CLINICAL TRIALS LLC | Not supplied | No dispute reported | 06/30/2026 | 1187888470 |
| Principal investigator 1 | PFIZER INC. | $900.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745262 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745266 |
| Principal investigator 1 | PFIZER INC. | $125.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228745617 |
| Principal investigator 1 | PFIZER INC. | $281.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745689 |
| Principal investigator 1 | PFIZER INC. | $900.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745994 |
| Principal investigator 1 | PFIZER INC. | $1,432.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746579 |
| Principal investigator 1 | PFIZER INC. | $1,977.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228746978 |
| Principal investigator 1 | PFIZER INC. | $281.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747142 |
| Principal investigator 1 | PFIZER INC. | $1,760.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228747966 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228748085 |
| Principal investigator 1 | PFIZER INC. | $1,642.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228749782 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228749808 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228750380 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228750699 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 01/15/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228751162 |
| Principal investigator 1 | PUMA BIOTECHNOLOGY, INC. | $3,000.00 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE, LLC | ALI-4201 | No dispute reported | 06/30/2026 | 1251753212 |